MRVI Q3 2024 Earnings — Maravai LifeSciences Holdings, Inc. Revenue & Financial Results | Market Cap Arena

MRVIMaravai LifeSciences Holdings, Inc.

$999M

Q3 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$65M-2.5% YoY

Gross Profit

$28M43.5% margin

Operating Income

-$169M-259.4% margin

Net Income

-$99M-151.9% margin

EPS (Diluted)

$-0.70

QoQ Revenue Growth

-11.2%

Cash Flow

Operating Cash Flow

$13M

Free Cash Flow

$4M

Stock-Based Comp.

$13M

Balance Sheet

Total Assets

$1.3B

Total Liabilities

$665M

Stockholders' Equity

$345M

Cash & Equivalents

$578M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$65M	$67M	-2.5%
Gross Profit	$28M	$30M	-6.0%
Operating Income	-$169M	-$15M	-996.9%
Net Income	-$99M	-$6M	-1432.6%

Revenue Segments

Nucleic Acid Production Segment

$50M77%

Biologics Safety Testing Segment

$15M23%

Geographic Segments

North America

$35M53%

Asia Pacific

$23M35%

EMEA

$7M11%

Latin And Central America

$125,0000%